New acid blocker takes on standard drug for Post-Surgery reflux

NCT ID NCT06955520

Recruiting now Disease control Sponsor: Asian Institute of Gastroenterology, India Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a newer acid-reducing drug, Vonaprazan, heals acid reflux better than the standard drug Esomeprazole in people who had POEM surgery for achalasia. About 300 adults with moderate to severe esophagitis will take one of the two drugs for 8 weeks. The goal is to see which drug heals the esophagus more effectively and improves symptoms like heartburn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vonaprazan (a potassium-competitive acid blocker) and Esomeprazole (a proton pump inhibitor)
What this could lead to: If Vonaprazan works better, it could offer a more effective way to heal acid reflux after POEM surgery, reducing symptoms and the need for stronger treatments.
What could go wrong: This is a relatively small, early-stage comparison. Vonaprazan may not prove significantly better than the standard drug, and results may not apply to all GERD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease peptic esophagitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GERD

Contacts and locations

Locations

Asian Institute of Gastroenterology /Aig Hospitals
RECRUITING

Hyderabad, Telangana, 500082, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.